

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



The Role of the Neuropeptide Substance P in the Pathogenesis of Parkinson's Disease

Emma Thornton and Robert Vink
University of Adelaide
Australia

1. Introduction

Parkinson's disease (PD) was first described by James Parkinson in 1815 as "shaking palsy syndrome". Today, it is the second most common neurodegenerative disorder, with a lifetime risk of 1 in 45 of developing the debilitating disease and currently affecting 1% of the population over the age of 65 (G. Alves, et al., 2008).

PD is characterized by a slow and progressive loss of the pigmented dopaminergic neurons of the substantia nigra pars compacta (SNc). This loss of dopaminergic neurons is often accompanied by a loss of the noradrenergic pigmented neurons of the locus ceruleus, and in the later stages of the disease, both the cholinergic neurons of the nucleus basalis of Meynert and the serotonergic neurons of the dorsal raphe nucleus may also degenerate (Marey-Semper, et al., 1995). In remaining DA neurons proteinaceous cytoplasmic inclusions called Lewy bodies (LBs) are found. They are filamentous in nature and predominantly contain alpha-synuclein and ubiquitin proteins (Bennett, 2005). Although LBs are also found in other diseases, such as diffuse Lewy body dementia and incidental Lewy body disease, they are considered to be the pathological hallmark of PD (Greenfields, 1992).

The dopaminergic neurons of the SNc are part of the basal ganglia (BG), an integral part of the brain that ensures smooth execution of movement. Accordingly motor symptoms such as resting tremor, bradykinesia, akinesia, rigidity and postural instability are most common. Degeneration of dopaminergic neurons is slow, with progressive loss of about 5% per year (Blum, et al., 2001), suggesting that a therapy could halt or slow down the progression of the disease, but to date no known neuroprotective therapy exists. Instead, current treatment involves managing patients' symptoms. Normally this treatment is L-DOPA, the precursor to DA. The rationale for this therapy is to restore DA levels to near normal and therefore restore normal function of the basal ganglia for a period of time. Unfortunately, following prolonged use many patients fail to maintain a good response and often experience "wearing off" effects, which is a reduction in the length of time that L-DOPA effectively alleviates symptoms (Krasnova, et al., 2000). Furthermore, motor complications like dyskinesia, or involuntary movements, occur in approximately 50-80% of PD patients who have been on L-DOPA for more than 5-10 years. These side effects are often more debilitating than the original motor deficits (Chen, et al., 2004).

In addition to the loss of dopaminergic neurons, there is also a reduction in the expression of the neuropeptide, substance P (SP), an important neurotransmitter in the BG, which is essential for proper execution of function. However, this loss of SP has been observed in

animal and human studies under conditions that represented end-stage PD. We suggest that this late loss of SP content is an event secondary to dopamine neuronal death. In the early phase of the disease, we propose that SP expression may actually be increased, and that this increase in SP may contribute to dopaminergic cell death through its effects on inflammatory processes and blood brain barrier (BBB) dysfunction. This review critically analyses the evidence that SP contributes to the pathogenesis of PD.

2. The basal ganglia

The BG is a group of nuclei located within the midbrain whose primary function is the smooth execution of movement. Apart from the substantia nigra, which also contains the pars reticulata (SNr), the BG nuclei include the striatum (caudate/putamen), the globus pallidus, both internal (GPi) and external segments (GPe), and the subthalamic nucleus (STN). Although the thalamus is not strictly part of the BG, it is fundamental to its function. In order for the BG to function correctly, it requires the two main signalling pathways, the direct and indirect pathway, to act in concert.

The direct signalling pathway involves an excitatory glutamatergic signal being sent from the cortex to striatal GABAergic projection neurons that project to the GPi and SNr resulting in inhibition of these nuclei. These nuclei also send inhibitory GABAergic signals, the inhibition of GPi/SNr neurons results in decreased inhibitory output to the thalamus. Consequently, the activity of thalamic neurons are increased causing excitatory glutamatergic signals to be sent back to the cortex, reinforcing cortical activity. The direct pathway therefore provides positive feedback for the cortex to allow movement (Silkis, 2001). Alternatively, the indirect pathway involves an excitatory signal being sent from the cortex to striatal inhibitory GABAergic neurons that project to the GPe, resulting in increased inhibition of the GPe neurons. As these neurons send an inhibitory GABAergic signal to the STN, the inhibition of these neurons leads to increased glutamatergic excitatory output from the STN. Subsequently, the STN sends excitatory signals to the inhibitory GPi and SNr neurons increasing their inhibitory output to the thalamus ensuring inhibition of the thalamic neurons and thus inhibition of cortical activity. The indirect pathway is therefore involved in negative feedback to the cortex and inhibition of the posture keeping the limb there (Sil'kis, 2002). These signalling pathways are kept in balance to ensure the almost simultaneous inhibition of the original position and initiation of the new required movement.

The direct and indirect signalling pathways are kept in balance by the dopaminergic input from the SNc to the striatum, known as the nigrostriatal pathway. The striatal GABAergic projection neurons express both DA receptors, namely D1 and D2 (Yelnik, 2002), although there are higher numbers of D1 receptors on the projections neurons involved in the direct pathway and D2 receptors for the indirect pathway (Aizman, et al., 2000). Through binding to D1 receptors, DA increases cAMP production, thereby reinforcing the activity of the direct pathway. In contrast, when DA binds to D2 receptors, cAMP production is reduced, creating a reversal of the activity of the nuclei within the indirect pathway and a decrease in its activity. As the indirect pathway is involved in negative feedback to the cortex, DA causes increased activity of the cortical neurons and reinforcement of cortical activity (van der Stelt and Di Marzo, 2003). Thus, the release of striatal DA within the nigrostriatal pathway of the BG allows fine-tuning of movement control and smooth execution of movement.

2.1 Basal ganglia function in Parkinson's disease

The initial loss of dopaminergic neurons in early PD does not decrease striatal DA activity due to pre- and post-synaptic compensatory responses of the dopaminergic system. These include upregulation of D1 and D2 dopamine receptor expression, which have a lower threshold for activation than normal, and an increase in activity of the surviving dopaminergic neurons (Deumens, et al., 2002). These compensatory mechanisms are able to sustain normal activity until approximately 50% of DA neurons and 80% of the total striatal DA is lost. Once this threshold level of striatal DA is reached, the direct and indirect signalling pathways become imbalanced producing a subsequent increase in the indirect signalling pathway and a decrease in the direct signalling pathway (Contreras-Vidal and Stelmach, 1996, Wardas, et al., 2003). Although these pathways also control the limbic system, the deficiency of DA in PD is heterogenous and DA is predominantly lost in the putamen area of the striatum, which is mainly involved in motor function of the BG. Therefore, PD is a hypokinetic disorder where the decreased activity of the direct pathway and increased activity of the indirect pathway results in a lack of movement as the common symptom (Silkis, 2001).

The BG does not only contain classical neurotransmitters such as glutamate, GABA and DA, but it also involves neuropeptides such as SP, neurokinin A (NKA) and the opioids enkephalin and dynorphin that act together for the fine-tuning of BG pathways (Graybiel, 1990, Hauber, 1998). These neurotransmitters can be segregated into the two pathways, with SP, NKA and dynorphin located in the GABAergic projection neurons of the direct pathway, whereas enkephalin is found within the striatal GABAergic projections neurons of the indirect pathway. Accordingly, in PD the change in activity of signalling pathways creates abnormal levels of these neurotransmitters. Changes in SP may be particularly important with respect to PD.

3. Substance P

Substance P was first discovered in 1934 by Gaddum and Schild, as the active principle in a stable dry powder. In 1936, Von Euler suggested the peptidergic nature of SP as its activity was stopped following digestion with trypsin, although later it was discovered that the degradation of SP was due to chymotrypsin as SP is trypsin-resistant (Leeman and Ferguson, 2000). Consequently it became part of the tachykinin family of which NKA and neurokinin B (NKB) are also members. Tachykinins are located in capsaicin-sensitive neurons, also known as primary sensory neurons, within the CNS, peripheral tissue and non-neuronal cells including endothelial cells and inflammatory cells (Hokfelt, et al., 2001). Within the brain there is a heterogeneous distribution of SP, with higher levels found in the grey matter. The highest concentration of SP is actually found within the SN (Ribeiro-da-Silva and Hokfelt, 2000), where SP immunoreactivity in the SNc is 25% higher than that in the SNr (Sutoo, et al., 1999). Also, within the BG SP expression is high within the internal segment of the globus pallidus.

Tachykinins share a common terminal sequence, Phe-X-Gly-Leu-Met-NH₂, where X is Phe or Val (Harrison and Geppetti, 2001, Saria, 1999). This sequence is essential for their biological activity and thus there is a certain amount of cross reactivity amongst the tachykinin receptors and their ligands (Gerard, et al., 1991, Khawaja and Rogers, 1996). Each tachykinin has varying affinities for the tachykinin receptors, with SP having the greatest affinity for the tachykinin NK1 receptor (NK₁), NKA to NK₂ and NKB to NK₃ tachykinin receptors.

Tachykinin receptors have a rhodopsin-like membrane structure comprising of 7 hydrophobic transmembrane domains connected by extra- and intracellular loops and coupled to G-proteins (Harrison and Geppetti, 2001). NK₁ and NK₃ receptors are mainly found in the CNS, but are also present in peripheral tissues (Otsuka and Yoshioka, 1993). Throughout the brain, greatest NK₁ receptor immunoreactivity is found in the striatum, nucleus accumbens, hippocampus, hypothalamus and the raphe nuclei (Harrison and Geppetti, 2001), whereas NK₃ receptors are most abundant in the cortex and on glial cells (Yip and Chahl, 2000). In contrast, NK₂ receptors are widely distributed in the peripheral nervous system (PNS) especially in the smooth muscle of the respiratory, gastrointestinal and urinary tracts (Maggi, 1995).

SP binds to the hydrophobic ligand-binding pocket within the extracellular loops of the NK₁ receptor causing rapid internalisation of the ligand and its receptor (Harrison and Geppetti, 2001). Ligand binding stimulates the activity of adenylate cyclase and the conversion of adenosine triphosphate (ATP) to adenosine monophosphate, which in turn activates phospholipase C_B (PLC_B) (Saria, 1999). Activation of PLC_B results in an increased turnover of intracellular inositol 1,4,5-triphosphate and a subsequent elevation of intracellular calcium (Ca²⁺) (Gerard, et al., 1991). The NK₁ receptor has a 5' untranslated region containing a cyclic AMP (cAMP) binding protein that responds to elevated levels of cAMP and Ca²⁺ by increasing gene transcription of SP (Saria, 1999). This creates a positive feedback loop for SP production and release. Conversely, SP may also block potassium channels causing membrane depolarisation and/or activate NK₁ autoreceptors to inhibit its own release (Harrison and Geppetti, 2001).

SP is synthesized from the preprotachykinin (PPT)-A gene, which also encodes NKA, neuropeptide K (NPK) and neuropeptide Y (NPY), the latter two being elongated versions of NKA (Hokfelt, et al., 2001). Alternative splicing of the PPT-A gene results in 3 distinct mRNAs: α -PPT-A, β -PPT-A and γ -PPT-A. Although all 3 PPT-A mRNAs encode for SP (Harrison and Geppetti, 2001), α -PPT-A mRNA is the main isoform of mRNA in the brain, whereas α - and γ -PPT-A mRNA are primarily expressed within the periphery (Severini, et al., 2002). NKB is encoded by the PPT-B gene and like PPT-A gene is conserved amongst species (Hoyle, 1998).

Synthesis of SP occurs within ribosomes in cell bodies of the dorsal root ganglia before it is packaged into large dense core vesicles with processing enzymes called convertases, which cleave at Lys-Arg, Arg-Arg or Arg-Lys bonds to release the active form of SP (Severini, et al., 2002). When stimulated, SP-containing vesicles undergo retrograde axonal transport to the terminal endings in both the CNS and PNS, where they undergo final enzymatic processing and post-translational enzymatic modifications such as C-terminal amidation (Hokfelt, et al., 2000). As previously mentioned, SP release is triggered by a small rise in intracellular Ca²⁺, which will increase the pH within the vesicle resulting in alkalinisation and release of SP by exocytosis (Otsuka and Yoshioka, 1993). NK₁ receptors are also synthesized and then anterogradely transported along axons to peripheral and perhaps central terminals. Thus, upon release SP can activate the postsynaptic NK₁ receptors (Malcangio and Bowery, 1999).

3.1 Substance P regulation of basal ganglia function

Substance P is important in regulating the function of the SN and BG (Bell, et al., 1998, Maubach, et al., 2001) where it acts as an excitatory neurotransmitter (Napier, et al., 1995). Like in other areas of the brain, SP is released in the BG due to an elevation in Ca²⁺ (Otsuka

and Yoshioka, 1993). Once released, it may bind to NK₁ receptors located on striatal interneurons to increase the firing rate and depolarise membrane potentials causing the release of other BG neurotransmitters such as GABA, glutamate and acetylcholine (Aosaki and Kawaguchi, 1996, Bailey, et al., 2004, Kemel, et al., 2002).

It is now known that NK₁ receptors are also located on 90% of DA neurons in the SNc (L-W. Chen, et al., 2004). However, earlier studies reported that there was an absence of NK₁ receptors in the SN and a mismatch between SP and NK₁ in this region (Humpel and Saria, 1993). This mismatch in the expression and binding of SP in the SN was subsequently thought to be due to the rapid internalisation of the SP/NK₁ complex following SP binding resulting in NK₁ being mainly located intracellularly (Levesque, et al., 2007). Accordingly, through binding to NK₁ receptors on dopaminergic neurons, SP can directly cause the release of DA within the striatum (Galarraga, et al., 1999, Orosz and Bennett, 1990, Reid, et al., 1990a, Reid, et al., 1990b). Moreover, as DA receptors are located on SP-containing striatal projection neurons, DA or DA agonists can potentiate SP release within the SN (Humpel and Saria, 1993). Therefore, SP and DA within the BG are modulated through a positive feedback mechanism. Accordingly, an injection of SP into the BG induces behavioural effects such as sniffing, rearing, grooming and increased motor activity in rats by promoting striatal DA release (Saria, 1999). However in PD, the loss of striatal DA interrupts this positive feedback mechanism and therefore a reduction in striatal SP gene transcription and SP protein content within the SN has been observed.

3.2 Substance P expression in Parkinson's disease

Post-mortem immunohistochemical studies have shown that there is a loss of SP content in the striatum and SN in PD brains (De Ceballos and Lopez-Lozano, 1999, Mauborgne, et al., 1983, Nisbet, et al., 1995, Sivam, 1991, Tenovuo, et al., 1984). Along with this loss of SP, there is also a significant deficit of NK₁ receptors in the putamen and GP of PD patients compared to aged matched controls (Fernandez, et al., 1994). Moreover, in a case of idiopathic PD, where the person died shortly after diagnosis from an unrelated cause, LBs were observed in surviving SP-containing neurons of the pedunculopontine tegmental nucleus, suggesting that these SP neurons were affected early in PD (Gai, et al., 1991).

Decrease in SP has also been extensively studied in the 6-OHDA rodent and MPTP non-human primate models of PD. Like in human PD, there is a decrease in SP content in the SN and striatum in these animal models (Bannon, et al., 1995, Schwarting and Huston, 1996). However, in a study by Orosz and Bennet in 1990 using the 6-OHDA rat model of PD, it was shown that although there was a decline in SP-immunoreactivity and SP mRNA in tissue levels of the SN, there was a rise in SP-immunoreactivity in the extracellular space of the SN. Subsequently, it was suggested that this rise was a compensatory mechanisms for the loss of intracellular SP (Orosz and Bennett, 1990). This was the first study to show an increase in extracellular SP during PD. Due to the tissue loss of SP, 6-OHDA animals were given replacement SP treatment into either the lateral ventricle or directly into the SN restoring striatal DA content (Krasnova, et al., 2000). Additionally, pre-treatment with SP assisted the recovery from a 6-OHDA lesion. The authors suggested that this was due to prolonged changes in SP release that helped to negate the tissue loss of SP caused by 6-OHDA (Nikolaus, et al., 1997). Thus basal levels of SP are fundamental for proper function.

In the non-human primate MPTP model of PD, which represents the model most similar to human PD, it was shown that there was a reduction in striatal SP gene expression and that

this deficiency in SP correlated with the degree of motor symptoms present (Wade and Schneider, 2001). However when primates were treated with L-DOPA the decrease in SP gene expression was reversed (Herrero, et al., 1995).

It is important to note that these studies have all been undertaken in post-mortem tissue or in models that replicate the end stage of the disease. Therefore, the SP changes observed may be a secondary effect due to the loss of DA input into the striatum and the activation of the direct pathway. Indeed, research in our laboratory has shown that SP may actually be increased in the early stages of PD. In nigrostriatal organotypic cell culture, 6-OHDA treatment caused an immediate and prolonged elevation in SP content that was significantly correlated with lactate dehydrogenase content, a marker of cell death. Furthermore, the 6-OHDA induced cell death was prevented by treatment with an NK₁ receptor antagonist (Thornton, et al., 2010).

Subsequent *in vivo* studies using the rodent striatal 6-OHDA model also measured SP content in the striatum and SN at days 3 and 7 following lesioning using an enzyme-linked immunosorbent assay (ELISA) method, which determines SP content from a standardized amount of protein (Figure 1). Despite the difference in SP content between the hemispheres in sham (control) animals, there was an apparent increase in SP content in the contralateral (left) and ipsilateral (right) striatum at both 3 and 7 days following 6-OHDA administration. However, SP content was not elevated within the SN until day 7 following 6-OHDA striatal lesions. Dopaminergic neuronal loss as assessed by tyrosine hydroxylase immunoreactivity was also not apparent at day 3 but had begun by day 7 and was significant by day 14 post-lesion. Nonetheless, a small loss of striatal DA terminals was observed by day 3. These results suggest that increased SP expression may contribute to the loss of dopaminergic terminals and neurons, however dopaminergic cell loss must also have initiated an increase in SP content within the SN. Furthermore, as the majority of dopaminergic degeneration occurs from day 7 to 14, the rise in SP content may act to potentiate this cell loss.




Fig. 1. Using an ELISA method, substance P content was semi-quantified within the striatum and substantia nigra following 6-OHDA intrastriatal injections. Results are displayed as mean+SEM (n=5/group).

Substance P has been associated with cell loss and functional deficits in other brain pathologies such as traumatic brain injury and stroke (Donkin, et al., 2009, R. J. Turner, et al., 2006). This detrimental effect of SP was credited to its ability to induce BBB breakdown

and the subsequent genesis of cerebral oedema (R. Turner and Vink, 2007). Although cerebral oedema does not occur in PD, a decrease in BBB integrity has recently been linked to dopaminergic cell loss and the progression of PD (Bartels, et al., 2008, Kortekaas, et al., 2005). Moreover, SP has been shown to play an integral role in the inflammatory response within both the peripheral and central nervous systems (R.V. Alves, et al., 1999). Recently, neuroinflammation has also received much interest for its potential role in DA degeneration and disease progression. We therefore hypothesize that SP may be involved in dopaminergic cell death in early PD by promoting neuroinflammation and BBB dysfunction.

4. Potential role for substance P in dopaminergic degeneration in PD

4.1 Inflammatory processes

Two of the main inflammatory cells within the brain are microglia and astrocytes. Resting microglia are important for maintaining cellular homeostasis, and once activated are involved in the removal of cellular debris (Mosley, et al., 2006, Rock and Peterson, 2006). However, activated microglia produce proinflammatory trophic factors and cytokines such as interleukin-1 (IL-1), IL-2, IL-6 and tumour necrosis factor- α (TNF- α), all of which are potentially cytotoxic (Blum, et al., 2001). Chronic activation of microglia and therefore prolonged expression of cytokines can be especially damaging to neurons. Indeed, activated microglia have been observed in post-mortem PD tissue and in experimental models long after the induction of PD (Depino, et al., 2003, Marinova-Mutafchieva, et al., 2009, McGeer and McGeer, 2008). Moreover, in human cases and animal models of PD a rise in these proinflammatory factors and cytokines has been demonstrated in the SN, striatum and cerebrospinal fluid (CSF) (Jenner and Olanow, 1998, Liu and Hong, 2003).

Activated microglia can also generate reactive oxygen species (ROS) such as hydrogen peroxide and superoxide (O_2^-) through activation of NADPH oxidase (Wu, et al., 2003). Under normal conditions this is important for the microglial role in brain immune surveillance and ability to kill foreign organisms that enter the brain. However, excessive production of ROS can result in oxidative damage to proteins, lipids and DNA, resulting in dopaminergic cell death (reviewed by (Mosley, et al., 2006)). In addition, microglia contain inducible NOS (iNOS), enabling the secretion of nitric oxide (NO). NO can react with ROS to form reactive nitrogen species (RNS) such as peroxynitrite ($ONOO^-$), which is more stable than O_2^- and can cross cell membranes and thus can be more damaging to cells than ROS. Indeed, by-products of oxidative damage are found in the SN of PD brains at post-mortem (Marsden and Olanow, 1998).

Usually, the SN contains large numbers of microglia compared to other areas of the brain. This is consistent with dopaminergic neurons already being in a state of oxidative stress due to the production of ROS during normal DA metabolism, making these neurons particularly vulnerable to insults (Berretta, et al., 2005, Liu and Hong, 2003, Olanow, et al., 2004). Moreover, oxidative damage by ROS and RNS is exacerbated in PD due to a deficiency of glutathione and superoxide dismutase, two of the main antioxidant enzymes that scavenge ROS, RNS and reduce H_2O_2 to its non-reactive state (Canals, et al., 2001).

Apart from causing damage to cellular structures, RNS and ROS may also cause mitochondrial dysfunction. In PD, a 30 to 40% decrease in complex I (NADH dehydrogenase) activity of the electron transport chain (ETC) is observed in mitochondria within the SN (Blum, et al., 2001, Squire, et al., 2003). The ETC, through oxidative phosphorylation, produces ATP, an important energy source for cell organelles, enzymes

and transport systems. Thus, mitochondrial dysfunction causes a bioenergetic deficit that leads to membrane depolarisation, disruption of Ca^{2+} homeostasis and further production of free radicals and ROS (Shults, 2004). Specifically, a reduction in ATP causes impairment of the mitochondrial membrane potential, and subsequent opening of the mitochondrial permeability transition pore. Pore opening stimulates the release of mitochondrial proteins, such as cytochrome c and apoptosis-inducing factor, that trigger apoptosis (Rego and Oliveira, 2003). Consistent with this, DA neurons are thought to die via apoptotic cell death cascades in PD (Olanow and Tatton, 1999).

With the loss of ATP production, there is also a consequential loss of the magnesium blockade of N-methyl-D-aspartate (NMDA) receptors, resulting in elevated levels of glutamate and NO (Q. Chen, et al., 1996). Dopaminergic neurons in the SN are rich in functional NMDA glutamate receptors and therefore affected by any change in glutamate levels (Olanow and Tatton, 1999). Glutamate, an excitatory amino acid, causes an increase in intracellular Ca^{2+} resulting in FR production, mitochondrial damage and activation of degradative enzymes. These enzymes, including proteases, endonucleases and phospholipases, result in degradation of plasma membranes, the cytoskeleton and nuclear material and subsequent cell death. This deleterious cascade of events, known as glutamate excitotoxicity, is also a major contributor to cell loss in PD (Beal, 1992).

Notably, production of ROS and RNS during inflammation and mitochondrial dysfunction are critically linked since activation of microglia can lead to mitochondrial dysfunction, and vice versa (Di Filippo, et al., 2010). The combined effects of these disease mechanisms in dopaminergic degeneration are further reinforced in experimental models of PD as the complex 1 inhibitor rotenone causes DA degeneration and microglial activation following either systemic or intracerebral administration (Gao, et al., 2003). Additionally, MPTP and 6-OHDA models also demonstrate both mitochondrial dysfunction and an exacerbated inflammatory response (Blum, et al., 2001, Chung, et al., 2010a).

Activation of microglia is not only a vicious cycle whereby the degeneration of neurons stimulates further microglial activation (Raivich, et al., 1999), it may also precede DA degeneration (Wojtera, et al., 2005). Activated microglia may prematurely phagocytose damaged DA neurons that may not have gone on to degenerate as evidence by the fact that phagocytotic CD68 positive microglia are observed prior to caspase-3 positive apoptotic DA neurons in the 6-OHDA model of PD (Marinova-Mutafchieva, et al., 2009).

The astrocytic response in PD has received less attention than microglia for its potential role in the pathogenesis of PD. Nevertheless, in all animal models of PD, there is an increase in glial fibrillary acidic protein immunoreactivity in both the striatum and SN, with the presence of reactive, hypertrophic astrocytes (Depino, et al., 2003, Takagi, et al., 2007). Furthermore, a 30% increase in these reactive astrocytes within the SN was seen in PD tissue at post-mortem (Wu, et al., 2003). However, activation of astrocytes may be both beneficial, through secretion of neurotrophic substances such as glial derived nerve factor and brain derived nerve factor, and detrimental through secretion of pro-inflammatory cytokines (Brahmachari, et al., 2006, Hirsch, 2000). These cytokines stimulate the activation of additional microglia or astrocytes, thereby further exacerbating the inflammatory response and tissue damage previously described for microglia (Chauhan, et al., 2008, Raivich, et al., 1999). In reactive astrocytes, myeloperoxidase produces RNS and damage to DA neurons (Choi, et al., 2005). However, the presence of astrocytes may be also beneficial as the density of astrocytes is low in the SNc compared to the ventral tegmental area, an area much less susceptible to DA damage in clinical and experimental models of PD. Nonetheless, reactive

astrocytes are thought to contribute to disease progression, although their exact role remains controversial (Chung, et al., 2010b).

The CNS immune response in PD can result in apoptosis of neurons by causing mitochondrial dysfunction and production of cytokines. An increase in cytokines, especially TNF α , can initiate apoptosis through binding at the tumour necrosis factor- α receptor 1 (TNF α R1), a known cell death receptor located on dopaminergic cell bodies in the SN (Mladenovic, et al., 2004).

4.1.1 Substance P and inflammation

Substance P and its NK₁ receptor have long been known to be important mediators of CNS inflammation (Harrison and Geppetti, 2001, Martin, et al., 1992). SP binding at NK₁ receptors expressed on microglia and astrocytes may directly result in the activation of these glial cells in the CNS (Mantyh, et al., 1989, Marriott, 2004). SP can also cause the indirect activation of astrocytes and microglia through its ability to promote cytokine and NO production, as they are able to modulate the activation of each other during the inflammatory response (Brahmachari, et al., 2006, Rodrigues, et al., 2001). Furthermore, pro-inflammatory cytokine production, for example, IL-1 β can upregulate the expression of NK₁ receptors on glial cells (Guo, et al., 2004). Due to its ability to modulate the inflammatory response, SP may play a critical role in inflammation-induced damage. Indeed, in bacterial diseases of the CNS, SP/NK₁ interactions exacerbate the glial immune responses through both initiating and progressing the subsequent inflammation (Chauhan, et al., 2008).

In vitro studies also have increased our understanding of the signal transduction pathways induced by SP in microglia and astrocytes and resulting in pro-inflammatory cytokine production. SP can stimulate the secretion of TNF- α from microglia and astrocytes following treatment with the endotoxin lipopolysaccharide (LPS) (Luber-Narod, et al., 1994). The presence of NK₁ receptors could not be demonstrated on microglia, therefore suggesting that this effect was mediated via the SP induced release of IL-1 from astrocytes, causing TNF- α release from both glial cell populations. However, the authors concede that their methods may have not have detected NK₁ receptors. Subsequent studies have shown functional NK₁ receptors expressed on murine microglia *in vitro* (Rasley, et al., 2002). The production of pro-inflammatory cytokines from glial cells has been shown to occur following the translocation of NF- κ B. SP by binding to NK₁ activated the NF- κ B pathway stimulating cytokine production (Lieb, et al., 1997). Moreover, SP has also been shown to induce IL-6 production by activating p39 MAPK pathway (Fiebich, et al., 2000).

The role of inflammation in dopaminergic cell loss is further confirmed by the efficacy of anti-inflammatory agents in PD as they have been shown to slow down disease progression (Qian, et al., 2010). A meta-analysis of peer reviewed data between 1966 and 2008 indicated NSAIDs may be slightly protective in PD through their ability to halt the pro-inflammatory response, prevent cyclooxygenase activity and scavenge ROS and RNS (Samii, et al., 2009). Furthermore, Minocycline, a microglial inhibitor, has advanced to phase III clinical trials (Tansey and Goldberg, 2010). These promising results suggest that inhibiting SP signalling through antagonism of the NK₁ receptor may reduce the inflammatory response in PD, thus offering a novel therapeutic target to slow the progression of PD.

4.2 Blood brain barrier dysfunction

Recently, BBB dysfunction has been implicated in the pathophysiology of PD. In clinical PD, p-glycoprotein function, a marker of BBB integrity, was reduced suggesting a loss of barrier

integrity (Bartels, 2008; Kortekaas 2005). The authors suggested that this loss of barrier function may contribute to the progression of PD. In the SN the BBB is known to be weaker than in other brain regions and consequently is easily disrupted (Ionov, 2008). Notably, dopaminergic neurons demonstrate a greater vulnerability to barrier breakdown. In a study by Rite and colleagues (2007), intracerebral injection of vascular endothelium growth factor (VEGF) into the SN and striatum caused BBB breakdown as assessed by fluorescently tagged FITC-albumin infiltration. This resulted in dopaminergic terminal degeneration and apoptotic markers, caspase-3 and TUNEL expression in DA neurons. In contrast, injection of VEGF into the hippocampus caused no apparent apoptosis of hippocampal neurons (Rite, et al., 2007).

A correlation between BBB breakdown, the astrocytic and microglial response and dopaminergic degeneration has been previously described (Tomas-Camardiel, et al., 2004). In experimental models of PD, barrier dysfunction has been reported in MPTP, 6-OHDA and rotenone models of PD (Carvey, et al., 2005, Chao, et al., 2009, Ravenstijn, et al., 2008) and has also been observed in our own studies (unpublished). Further evidence for the BBB and CNS inflammation contributing to dopaminergic cell death is that mesenchymal stem cell (MSC) transplantation was found to be protective to DA neurons in the MPTP model of PD (Chao, et al., 2009). MSC transplantation reduced microglial activation and restored BBB function as reflected in reduced FITC-labelled albumin leakage, and returned expression of tight junction proteins, claudin 1 and 5 expression back to basal levels. The authors attributed this beneficial effect of MSCs expression of TGF- β 1, which has an anti-inflammatory effect.

BBB dysfunction may also result in damage to DA neurons by allowing the influx of peripheral immune cells, such as blood borne macrophages, T-lymphocytes and leukocytes into the brain (Hunot, et al., 1999, Kortekaas, et al., 2005). Similar to CNS immune cells, peripheral immune cells secrete cytokines following the translocation of transcription factor NF- κ B. Accordingly, PD patients challenged with LPS had significantly exacerbated release of cytokines / chemokines from peripheral borne macrophage cells as compared to healthy controls (Reale, et al., 2009). Blood inflammatory cells such as neutrophils may also infiltrate through the disrupted BBB and activate microglia. Indeed, increased neutrophil infiltration, greater BBB permeability and decreased astrocyte numbers in SNc are thought to contribute to selective DA degeneration (Ji, et al., 2008). Furthermore, a study by Brochard and colleagues has shown that peripheral immune cells such as CD4⁺ T leukocytes are involved in MPTP induced cell death in mice while CD4⁺ null mice have reduced DA degeneration (Brochard, et al., 2009).

Thus, the infiltration and production of pro-inflammatory cytokines by peripheral cells can activate resident brain immune cells such as microglia. Therefore, not only do peripheral immune cells directly injure dopaminergic neurons, they can also indirectly activate microglia and astrocytes to further exacerbate inflammatory and cell death cascades. These results suggest that peripheral cytokine production and infiltration across the BBB may contribute to PD pathogenesis.

4.2.1 Substance P and blood brain barrier dysfunction

Along with its known role in modulating the peripheral immune response, SP is an important regulator of BBB integrity and can potentiate barrier breakdown through neurogenic inflammation. Neurogenic inflammation is a neurally elicited local

inflammatory response characterised by vasodilation, protein extravasation and tissue swelling, which can be induced by certain types of injury or infection (Vink, et al., 2003). It is caused by a release of calcitonin-gene related peptide (CGRP) and SP from primary sensory nerve fibers surrounding blood vessels with subsequent activation of NK₁ receptors on endothelial cells (Lever, et al., 2003). CGRP, the most potent vasodilator, increases blood flow, bringing cytokines and inflammatory mediators to the area (Woie, et al., 1993), whereas SP binding to NK₁ receptors increases vessel permeability, leading to plasma extravasation and BBB breakdown (Hokfelt, et al., 2001). Neurogenic inflammation has been well described in the periphery but has also recently been reported to occur in the CNS (Nimmo, et al., 2004, R. Turner and Vink, 2007).

Another mechanism whereby SP may affect BBB permeability is through histamine. SP instigates the release of histamine from mast cells, to further increase vessel permeability and extravasation (R.V. Alves, et al., 1999). Thus, SP plays a central role in mediating extravascular migration of inflammatory cells into inflamed tissue (Harrison and Geppetti, 2001). Interestingly in PD, patients demonstrate elevated plasma histamine levels (Coelho, et al., 1991) and intranigral injection of histamine results in DA cell death and glial cell activation (Vizuete, et al., 2000).

5. Conclusion

We conclude that SP may be involved in the pathogenesis of PD, particularly in relation to inflammation and BBB breakdown. We suggest that the reported loss of SP expression in PD may be a secondary effect due to the decrease in striatal dopamine and therefore the loss of the SP/dopaminergic positive feedback mechanism. In contrast, SP may actually be increased within the BG *early* in PD and induce nigral BBB breakdown through neurogenic inflammation, as well as contribute to local inflammatory responses. Therefore, treatment with a NK₁ receptor antagonist may be a novel neuroprotective agent to slow the progression of PD.

6. References

- Aizman, O., Brismar, H., Uhlen, P., Zettergren, E., Levey, A. I., Forssberg, H., Greengard, P. & Aperia, A., (2000). Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. *Nat Neurosci.* Vol. 3, No. 3, (Mar, 2000), pp. (226-30).
- Alves, G., Forsaa, E. B., Pedersen, K. F., Dreetz Gjerstad, M. & Larsen, J. P., (2008). Epidemiology of Parkinson's disease. *J Neurol.* Vol. 255 Suppl 5, No., (Sep, 2008), pp. (18-32).
- Alves, R. V., Campos, M. M., Santos, A. R. S. & Calixto, J. B., (1999). Receptor subtypes involved in tachykinin-mediated edema formation. *Peptides.* Vol. 20, No., 1999), pp. (921-927).
- Aosaki, T. & Kawaguchi, Y., (1996). Actions of substance P on rat neostriatal neurons in vitro. *J Neurosci.* Vol. 16, No. 16, (Aug 15, 1996), pp. (5141-53).
- Bailey, C. P., Maubach, K. A. & Jones, R. S., (2004). Neurokinin-1 receptors in the rat nucleus tractus solitarius: pre- and postsynaptic modulation of glutamate and GABA release. *Neuroscience.* Vol. 127, No. 2, 2004), pp. (467-79).

- Bannon, M. J., Brownschidle, L. A., Tian, Y., Whitty, C. J., Poosch, M. S., D'sa, C. & Moody, C. A., (1995). Neurokinin-3 receptors modulate dopamine cell function and alter the effects of 6-hydroxydopamine. *Brain Res.* Vol. 695, No., 1995), pp. (19-24).
- Bartels, A. L., Willemsen, A. T., Kortekaas, R., de Jong, B. M., de Vries, R., de Klerk, O., van Oostrom, J. C., Portman, A. & Leenders, K. L., (2008). Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. *J Neural Transm.* Vol. 115, No. 7, (Jul, 2008), pp. (1001-9).
- Beal, M. F., (1992). Mechanisms of excitotoxicity in neurologic diseases. *Faseb J.* Vol. 6, No. 15, (Dec, 1992), pp. (3338-44).
- Bell, M. I., Richardson, P. J. & Lee, K., (1998). Characterization of the mechanism of action of tachykinins in rat striatal cholinergic interneurons. *Neuroscience.* Vol. 87, No. 3, (Dec, 1998), pp. (649-58).
- Bennett, M. C., (2005). The role of alpha-synuclein in neurodegenerative diseases. *Pharmacol Ther.* Vol. 105, No. 3, (Mar, 2005), pp. (311-31).
- Berretta, N., Freestone, P. S., Guatteo, E., Castro, D. D., Geracitano, R., Bernardi, G., Mercuri, N. B. & Lipski, J., (2005). Acute Effects of 6-Hydroxydopamine on Dopaminergic Neurons of the Rat Substantia Nigra Pars Compacta In Vitro. *Neurotoxicology.* Vol., No., (May 9, 2005), pp.).
- Blum, D., Torch, S., Lambeng, N., Nissou, M., Benabid, A. L., Sadoul, R. & Verna, J. M., (2001). Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. *Prog Neurobiol.* Vol. 65, No. 2, (Oct, 2001), pp. (135-72).
- Brahmachari, S., Fung, Y. K. & Pahan, K., (2006). Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide. *J Neurosci.* Vol. 26, No. 18, (May 3, 2006), pp. (4930-9).
- Brochard, V., Combadiere, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthet, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J. M., Duyckaerts, C., Flavell, R. A., Hirsch, E. C. & Hunot, S., (2009). Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. *J Clin Invest.* Vol. 119, No. 1, (Jan, 2009), pp. (182-92).
- Canals, S., Casarejos, M. J., de Bernardo, S., Rodriguez-Martin, E. & Mena, M. A., (2001). Glutathione depletion switches nitric oxide neurotrophic effects to cell death in midbrain cultures: implications for Parkinson's disease. *J Neurochem.* Vol. 79, No. 6, (Dec, 2001), pp. (1183-95).
- Carvey, P. M., Zhao, C. H., Hendey, B., Lum, H., Trachtenberg, J., Desai, B. S., Synder, J., Zhu, Y. G. & Ling, Z. D., (2005). 6-hydroxydopamine-induced alteration in blood-brain barrier permeability. *Eur J Neurosci.* Vol. 22, No., 2005), pp. (1158-1168.).
- Chao, Y. X., He, B. P. & Tay, S. S., (2009). Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson's disease. *J Neuroimmunol.* Vol. 216, No. 1-2, (Nov 30, 2009), pp. (39-50).
- Chauhan, V. S., Sterka, D. G., Jr., Gray, D. L., Bost, K. L. & Marriott, I., (2008). Neurogenic exacerbation of microglial and astrocyte responses to *Neisseria meningitidis* and *Borrelia burgdorferi*. *J Immunol.* Vol. 180, No. 12, (Jun 15, 2008), pp. (8241-9).
- Chen, L.-W., Yung, K. K. L. & Chan, Y. S., (2004). Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the

- prevention and treatment of Parkinson's disease. *Current Drug Targets*. Vol. 5, No., 2004), pp. (1-10).
- Chen, Q., Veenman, C. L.&Reiner, A., (1996). Cellular expression of ionotropic glutamate receptor subunits on specific striatal neuron types and its implication for striatal vulnerability in glutamate receptor-mediated excitotoxicity. *Neuroscience*. Vol. 73, No. 3, (Aug, 1996), pp. (715-31).
- Choi, D. K., Pennathur, S., Perier, C., Tieu, K., Teismann, P., Wu, D. C., Jackson-Lewis, V., Vila, M., Vonsattel, J. P., Heinecke, J. W.&Przedborski, S., (2005). Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. *J Neurosci*. Vol. 25, No. 28, (Jul 13, 2005), pp. (6594-600).
- Chung, Y. C., Kim, S. R.&Jin, B. K., (2010a). Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. *J Immunol*. Vol. 185, No. 2, (Jul 15, 2010a), pp. (1230-7).
- Chung, Y. C., Ko, H. W., Bok, E., Park, E. S., Huh, S. H., Nam, J. H.&Jin, B. K., (2010b). The role of neuroinflammation on the pathogenesis of Parkinson's disease. *BMB Rep*. Vol. 43, No. 4, (Apr, 2010b), pp. (225-32).
- Coelho, M. H., Silva, I. J., Azevedo, M. S.&Manso, C. F., (1991). Decrease in blood histamine in drug-treated parkinsonian patients. *Mol Chem Neuropathol*. Vol. 14, No. 2, (Apr, 1991), pp. (77-85).
- Contreras-Vidal, J. L.&Stelmach, G. E., (1996). Mini Review: Effects of Parkinsonism on motor control. *Life Sciences*. Vol. 58, No. 3, 1996), pp. (165-176).
- De Ceballos, M. L.&Lopez-Lozano, J. J., (1999). Subgroups of parkinsonian patients differentiated by pertidergic immunostaining of caudate nuclei biopsies. *Peptides*. Vol. 20, No., 1999), pp. (249-257).
- Depino, A. M., Earl, C., Kaczmarczyk, E., Ferrari, C., Besedovsky, H., del Rey, A., Pitossi, F. J.&Oertel, W. H., (2003). Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. *Eur J Neurosci*. Vol. 18, No. 10, (Nov, 2003), pp. (2731-42).
- Deumens, R., Blokland, A.&Prickaerts, J., (2002). Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. *Exp Neurol*. Vol. 175, No. 2, (Jun, 2002), pp. (303-17).
- Di Filippo, M., Chiasserini, D., Tozzi, A., Picconi, B.&Calabresi, P., (2010). Mitochondria and the link between neuroinflammation and neurodegeneration. *J Alzheimers Dis*. Vol. 20 Suppl 2, No., 2010), pp. (S369-79).
- Donkin, J. J., Nimmo, A. J., Cernak, I., Blumbergs, P. C.&Vink, R., (2009). Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury. *J Cereb Blood Flow Metab*. Vol. In press, No., 2009), pp.).
- Fernandez, A., de Ceballos, M. L., Jenner, P.&Marsden, C. D., (1994). Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients. *Neuroscience*. Vol. 61, No. 1, (Jul, 1994), pp. (73-9).
- Fiebich, B. L., Schleicher, S., Butcher, R. D., Craig, A.&Lieb, K., (2000). The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-kappa B. *J Immunol*. Vol. 165, No. 10, (Nov 15, 2000), pp. (5606-11).

- Gai, W. P., Halliday, G. M., Blumbergs, P. C., Geffen, L. B. & Blessing, W. W., (1991). Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson's disease. *Brain*. Vol. 114 (Pt 5), No., (Oct, 1991), pp. (2253-67).
- Galarraaga, E., Hernandez-Lopez, S., Tapia, D., Reyes, A. & Bargas, J., (1999). Action of substance P (neurokinin-1) receptor activation on rat neostriatal projection neurons. *Synapse*. Vol. 33, No. 1, (Jul, 1999), pp. (26-35).
- Gao, H. M., Liu, B. & Hong, J. S., (2003). Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. *J Neurosci*. Vol. 23, No. 15, (Jul 16, 2003), pp. (6181-7).
- Gerard, N. P., Garraway, L. A., Eddy, J., R.L., Shows, T. B., Iijima, H., Paquet, J.-L. & Gerard, C., (1991). Human substance P receptor(NK-1): Organisation of the gene, chromosome localization, and functional expression of cDNA clones. *Biochemistry*. Vol. 30, No. 44, 1991), pp. (10640-10646).
- Graybiel, A. M., (1990). Neurotransmitters and neuromodulators in the basal ganglia. *TINS*. Vol. 13, No. 7, 1990), pp. (244-254).
- Guo, C. J., Douglas, S. D., Gao, Z., Wolf, B. A., Grinspan, J., Lai, J. P., Riedel, E. & Ho, W. Z., (2004). Interleukin-1beta upregulates functional expression of neurokinin-1 receptor (NK-1R) via NF-kappaB in astrocytes. *Glia*. Vol. 48, No. 3, (Nov 15, 2004), pp. (259-66).
- Harrison, S. & Geppetti, P., (2001). Review: Substance P. *The International Journal of Biochemistry & Cell Biology*. Vol. 33, No., 2001), pp. (555-576).
- Hauber, W., (1998). Involvement of basal ganglia transmitter systems in movement initiation. *Prog Neurobiol*. Vol. 56, No. 5, (Dec, 1998), pp. (507-40).
- Herrero, M.-T., Augood, S. J., Hirsch, E. C., Javoy-Agid, F., Luquin, M. R., Agid, Y., Obeso, J. A. & Emson, P. C., (1995). Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. *Neurosci*. Vol. 68, No. 4, 1995), pp. (1189-1198).
- Hirsch, E. C., (2000). Glial cells and Parkinson's disease. *J Neurol*. Vol. 247 Suppl 2, No., (Apr, 2000), pp. (II58-62).
- Hokfelt, T., Broberger, C., Xu, Z.-Q. D., Sergeev, V., Ubink, R. & Diez, M., (2000). Neuropeptides- an overview. *Neuropharmacology*. Vol. 39, No., 2000), pp. (1337-1356).
- Hokfelt, T., Pernow, B. & Wahren, J., (2001). Substance P: a pioneer amongst neuropeptides. *J of Internal Medicine*. Vol. 249, No., 2001), pp. (27-40).
- Hoyle, C. H., (1998). Neuropeptide families: evolutionary perspectives. *Regul Pept*. Vol. 73, No. 1, (Jan 2, 1998), pp. (1-33).
- Humpel, C. & Saria, A., (1993). Intranigral injection of selective neurokinin-1 and neurokinin-3 but not neurokinin-2 receptor agonists biphasically modulate striatal dopamine metabolism but not striatal preprotachykinin-A mRNA in the rat. *Neurosci Lett*. Vol. 157, No. 2, (Jul 23, 1993), pp. (223-6).
- Hunot, S., Dugas, N., Faucheux, B., Hartmann, A., Tardieu, M., Debre, P., Agid, Y., Dugas, B. & Hirsch, E. C., (1999). FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. *J Neurosci*. Vol. 19, No. 9, (May 1, 1999), pp. (3440-7).
- Ionov, I. D., (2008). Self-amplification of nigral degeneration in Parkinson's disease: a hypothesis. *Int J Neurosci*. Vol. 118, No. 12, (Dec, 2008), pp. (1763-80).

- Jenner, P. & Olanow, C. W., (1998). Understanding cell death in Parkinson's disease. *Ann Neurol.* Vol. 44, No. 3 Suppl 1, (Sep, 1998), pp. (S72-84).
- Ji, K. A., Eu, M. Y., Kang, S. H., Gwag, B. J., Jou, I. & Joe, E. H., (2008). Differential neutrophil infiltration contributes to regional differences in brain inflammation in the substantia nigra pars compacta and cortex. *Glia.* Vol. 56, No. 10, (Aug 1, 2008), pp. (1039-47).
- Kemel, M. L., Perez, S., Godeheu, G., Soubrie, P. & Glowinski, J., (2002). Facilitation by endogenous tachykinins of the NMDA-evoked release of acetylcholine after acute and chronic suppression of dopaminergic transmission in the matrix of the rat striatum. *J Neurosci.* Vol. 22, No. 5, (Mar 1, 2002), pp. (1929-36).
- Khawaja, A. M. & Rogers, D. F., (1996). Tachykinins: receptor to effector. *Int J Biochem Cell Biol.* Vol. 28, No. 7, 1996), pp. (721-738).
- Kortekaas, R., Leenders, K. L., van Oostrom, J. C., Vaalburg, W., Bart, J., Willemsen, A. T. & Hendrikse, N. H., (2005). Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. *Ann Neurol.* Vol. 57, No. 2, (Feb, 2005), pp. (176-9).
- Krasnova, I. N., Bychkov, E. R., Lioudyno, V. I., Zubareva, O. E. & Dambinova, S. A., (2000). Intracerebroventricular administration of Substance P increases dopamine content in the brain of 6-hydroxydopamine-lesioned rats. *Neurosci.* Vol. 95, No. 1, 2000), pp. (113-117).
- Leeman, S. E. & Ferguson, S. L., (2000). Substance P: an historical perspective. *Neuropeptides.* Vol. 34, No. 5, 2000), pp. (249-254).
- Lever, I. J., Grant, A. D., Pezet, S., Gerard, N. P., Brain, S. D. & Maccangio, M., (2003). Basal and activity-induced release of substance P from primary afferent fibers in NK₁ receptor knockout mice: evidence for negative feedback. *Neuropharmacology.* Vol. 45, No. 8, 2003), pp. (1101-1110).
- Levesque, M., Wallman, M. J., Parent, R., Sik, A. & Parent, A., (2007). Neurokinin-1 and neurokinin-3 receptors in primate substantia nigra. *Neurosci Res.* Vol. 57, No. 3, (Mar, 2007), pp. (362-71).
- Lieb, K., Fiebich, B. L., Berger, M., Bauer, J. & Schulze-Osthoff, K., (1997). The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. *J Immunol.* Vol. 159, No. 10, (Nov 15, 1997), pp. (4952-8).
- Liu, B. & Hong, J. S., (2003). Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. *J Pharmacol Exp Ther.* Vol. 304, No. 1, (Jan, 2003), pp. (1-7).
- Luber-Narod, J., Kage, R. & Leeman, S. E., (1994). Substance P enhances the secretion of tumor necrosis factor-alpha from neuroglial cells stimulated with lipopolysaccharide. *J Immunol.* Vol. 152, No. 2, (Jan 15, 1994), pp. (819-24).
- Maggi, C. A., (1995). The mammalian tachykinin receptors. *Gen Pharmac.* Vol. 26, No. 5, 1995), pp. (911-944).
- Maccangio, M. & Bowery, N. G., (1999). Peptide autoreceptors: does an autoreceptor exist for substance P. *TiPS.* Vol. 20, No., 1999), pp. (405-407).
- Mantyh, P. W., Johnson, D. J., Boehmer, C. G., Catton, M. D., Vinters, H. V., Maggio, J. E., Too, H. P. & Vigna, S. R., (1989). Substance P receptor binding sites are expressed by glia in vivo after neuronal injury. *Proc Natl Acad Sci U S A.* Vol. 86, No. 13, (Jul, 1989), pp. (5193-7).

- Marey-Semper, I., Gelman, M. & Levi-Strauss, M., (1995). A selective toxicity toward cultured mesencephalic dopaminergic neurons is induced by the synergistic effects of energetic metabolism impairment and NMDA receptor activation. *J Neurosci.* Vol. 15, No. 9, (1995), pp. (5912-5918).
- Marinova-Mutafchieva, L., Sadeghian, M., Broom, L., Davis, J. B., Medhurst, A. D. & Dexter, D. T., (2009). Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease. *J Neurochem.* Vol. 110, No. 3, (Aug, 2009), pp. (966-75).
- Marriott, I., (2004). The role of tachykinins in central nervous system inflammatory responses. *Front Biosci.* Vol. 9, No., (Sep 1, 2004), pp. (2153-65).
- Marsden, C. D. & Olanow, C. W., (1998). The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. *Ann Neurol.* Vol. 44, No. 3 Suppl 1, (Sep, 1998), pp. (S189-96).
- Martin, F. C., Charles, A. C., Sanderson, M. J. & Merrill, J. E., (1992). Substance P stimulates IL-1 production by astrocytes via intracellular calcium. *Brain Res.* Vol. 599, No. 1, (Dec 18, 1992), pp. (13-8).
- Maubach, K. A., Martin, K., Smith, D. W., Hewson, L., Frankshun, R. A., Harrison, T. & Seabrook, G. R., (2001). Substance P stimulates inhibitory synaptic transmission in the guinea pig basolateral amygdala in vitro. *Neuropharmacology.* Vol. 40, No. 6, (May, 2001), pp. (806-17).
- Mauborgne, A., Javoy-Agid, F., Legrand, J. C., Agid, Y. & Cesselin, F., (1983). Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains. *Brain Res.* Vol. 268, No. 1, (May 23, 1983), pp. (167-70).
- McGeer, P. L. & McGeer, E. G., (2008). Glial reactions in Parkinson's disease. *Mov Disord.* Vol. 23, No. 4, (Mar 15, 2008), pp. (474-83).
- Mladenovic, A., Perovic, M., Raicevic, N., Kanazir, S., Rakic, L. & Ruzdijic, S., (2004). 6-Hydroxydopamine increases the level of TNF α and bax mRNA in the striatum and induces apoptosis of dopaminergic neurons in hemiparkinsonian rats. *Brain Res.* Vol. 996, No. 2, (Jan 23, 2004), pp. (237-45).
- Mosley, R. L., Benner, E. J., Kadiu, I., Thomas, M., Boska, M. D., Hasan, K., Laurie, C. & Gendelman, H. E., (2006). Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. *Clin Neurosci Res.* Vol. 6, No. 5, (Dec 6, 2006), pp. (261-281).
- Napier, T. C., Mitrovic, I., Churchill, L., Klitenick, M. A., Lu, X. Y. & Kalivas, P. W., (1995). Substance P in the ventral pallidum: projection from the ventral striatum, and electrophysiological and behavioral consequences of pallidal substance P. *Neuroscience.* Vol. 69, No. 1, (Nov, 1995), pp. (59-70).
- Nikolaus, S., Huston, J. P., Korber, B., Thiel, C. & Schwarting, R. K. W., (1997). Pretreatment with neurokinin substance P but not with cholecystokinin-8S can alleviate functional deficits of partial nigrostriatal 6-hydroxydopamine lesion. *Peptides.* Vol. 18, No. 8, (1997), pp. (1161-1168).
- Nimmo, A. J., Cernak, I., Heath, D. L., Hu, X., Bennett, C. J. & Vink, R., (2004). Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats. *Neuropeptides.* Vol. 38, No. 1, (Feb, 2004), pp. (40-7).

- Nisbet, A. P., Foster, O. J., Kingsbury, A., Eve, D. J., Daniel, S. E., Marsden, C. D. & Lees, A. J., (1995). Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. *Neuroscience*. Vol. 66, No. 2, (May, 1995), pp. (361-76).
- Olanow, C. W. & Tatton, W. G., (1999). Etiology and pathogenesis of Parkinson's disease. *Annu Rev Neurosci*. Vol. 22, No., 1999, pp. (123-144).
- Olanow, C. W., Agid, Y., Mizuno, Y., Albanese, A., Bonucelli, U., Damier, P., De Yebenes, J., Gershanik, O., Guttman, M., Grandas, F., Hallet, M., Hornykiewicz, O., Jenner, P., Katzenschlager, R., Langston, W. J., LeWitt, P., Melamed, E., Mena, M. A., Michel, P. P., Mytilineou, C., Obeso, J. A., Poewe, W., Quinn, N., Raisman-Vozari, R., Rajput, A. H., Rascol, O., Sampaio, C. & Stocchi, F., (2004). Levodopa in the treatment of Parkinson's disease: current controversies. *Movement Disorders*. Vol. 19, No. 9, 2004, pp. (997-1005).
- Orosz, D. & Bennett, J. P., Jr., (1990). Baseline and apomorphine-induced extracellular levels of nigral substance P are increased in an animal model of Parkinson's disease. *Eur J Pharmacol*. Vol. 182, No. 3, (Jul 17, 1990), pp. (509-14).
- Otsuka, M. & Yoshioka, K., (1993). Neurotransmitter functions of mammalian tachykinins. *Physiol Rev*. Vol. 73, No. 2, (Apr, 1993), pp. (229-308).
- Qian, L., Flood, P. M. & Hong, J. S., (2010). Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. *J Neural Transm*. Vol. 117, No. 8, (Aug, 2010), pp. (971-9).
- Raivich, G., Bohatschek, M., Kloss, C. U., Werner, A., Jones, L. L. & Kreutzberg, G. W., (1999). Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. *Brain Res Brain Res Rev*. Vol. 30, No. 1, (Jul, 1999), pp. (77-105).
- Rasley, A., Bost, K. L., Olson, J. K., Miller, S. D. & Marriott, I., (2002). Expression of functional NK-1 receptors in murine microglia. *Glia*. Vol. 37, No. 3, (Mar 1, 2002), pp. (258-67).
- Ravenstijn, P. G., Merlini, M., Hameetman, M., Murray, T. K., Ward, M. A., Lewis, H., Ball, G., Mottart, C., de Ville de Goyet, C., Lemarchand, T., van Belle, K., O'Neill, M. J., Danhof, M. & de Lange, E. C., (2008). The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments. *J Pharmacol Toxicol Methods*. Vol. 57, No. 2, (Mar-Apr, 2008), pp. (114-30).
- Reale, M., Iarlori, C., Thomas, A., Gambi, D., Perfetti, B., Di Nicola, M. & Onofri, M., (2009). Peripheral cytokines profile in Parkinson's disease. *Brain Behav Immun*. Vol. 23, No. 1, (Jan, 2009), pp. (55-63).
- Rego, A. C. & Oliveira, C. R., (2003). Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. *Neurochem Res*. Vol. 28, No. 10, (Oct, 2003), pp. (1563-74).
- Reid, M. S., Herrera-Marschitz, M., Hokfelt, T., Lindfors, N., Persson, H. & Ungerstedt, U., (1990a). Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms. *Exp Brain Res*. Vol. 82, No. 2, 1990a, pp. (293-303).
- Reid, M. S., Herrera-Marschitz, M., Hokfelt, T., Ohlin, M., Valentino, K. L. & Ungerstedt, U., (1990b). Effects of intranigral substance P and neurokinin A on striatal dopamine


- release--I. Interactions with substance P antagonists. *Neuroscience*. Vol. 36, No. 3, 1990b), pp. (643-58).
- Ribeiro-da-Silva, A.&Hokfelt, T., (2000). Neuroanatomical localisation of Substance P in the CNS and sensory neurons. *Neuropeptides*. Vol. 34, No. 5, 2000), pp. (256-271).
- Rite, I., Machado, A., Cano, J.&Venero, J. L., (2007). Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. *J Neurochem*. Vol. 101, No. 6, (Jun, 2007), pp. (1567-82).
- Rock, R. B.&Peterson, P. K., (2006). Microglia as a pharmacological target in infectious and inflammatory diseases of the brain. *J Neuroimmune Pharmacol*. Vol. 1, No. 2, (Jun, 2006), pp. (117-26).
- Rodrigues, R. W. P., Gomide, V. C.&Chadi, G., (2001). Astroglial and microglial reaction after partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine. *International Journal of Neuroscience*. Vol. 109, No., 2001), pp. (91-126).
- Samii, A., Etminan, M., Wiens, M. O.&Jafari, S., (2009). NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. *Drugs Aging*. Vol. 26, No. 9, 2009), pp. (769-79).
- Saria, A., (1999). The tachykinin NK₁ receptor in the brain: pharmacology and putative functions. *Eur J of Pharmacol*. Vol. 375, No., 1999), pp. (51-60).
- Schwartz, R. K.&Huston, J. P., (1996). Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. *Prog Neurobiol*. Vol. 49, No. 3, (Jun, 1996), pp. (215-66).
- Severini, C., Improta, G., Falconieri-Erspamer, G., Salvadori, S.&Erspamer, V., (2002). The tachykinin peptide family. *Pharmacol Rev*. Vol. 54, No., 2002), pp. (385-322).
- Shults, C. W., (2004). Mitochondrial dysfunction and possible treatments in Parkinson's disease-a review. *Mitochondrion*. Vol. 4, No. 5-6, (Sep, 2004), pp. (641-8).
- Sil'kis, I. G., (2002). A possible mechanism for the dopamine-evoked synergistic disinhibition of thalamic neurons via the "direct" and "indirect" pathways in the basal ganglia. *Neurosci Behav Physiol*. Vol. 32, No. 3, (May-Jun, 2002), pp. (205-12).
- Silkis, I., (2001). The cortico-basal ganglia-thalamocortical circuit with synaptic plasticity. II. Mechanism of synergistic modulation of thalamic activity via the direct and indirect pathways through the basal ganglia. *Biosystems*. Vol. 59, No. 1, (Jan, 2001), pp. (7-14).
- Sivam, S. P., (1991). Dopamine dependent decrease in enkephalin and substance P levels in basal ganglia regions of postmortem Parkinsonian brains. *Neuropeptides*. Vol. 18, No., 1991), pp. (201-207).
- Sutoo, D., Yabe, K.&Akiyama, K., (1999). Quantitative imaging of substance P in the human brain using a brain mapping analyzer. *Neurosci Res*. Vol. 35, No., 1999), pp. (339-346).
- Takagi, S., Hayakawa, N., Kimoto, H., Kato, H.&Araki, T., (2007). Damage to oligodendrocytes in the striatum after MPTP neurotoxicity in mice. *J Neural Transm*. Vol. 114, No. 12, 2007), pp. (1553-7).
- Tansey, M. G.&Goldberg, M. S., (2010). Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. *Neurobiol Dis*. Vol. 37, No. 3, (Mar, 2010), pp. (510-8).

- Tenovuo, O., Rinne, U. K. & Viljanen, M. K., (1984). Substance P immunoreactivity in the post-mortem parkinsonian brain. *Brain Res.* Vol. 303, No. 1, (Jun 11, 1984), pp. (113-6).
- Thornton, E., Tran, T. T. & Vink, R., (2010). A substance P mediated pathway contributes to 6-hydroxydopamine induced cell death. *Neurosci Lett.* Vol. 481, No. 1, (Aug 30, 2010), pp. (64-7).
- Tomas-Camardiel, M., Rite, I., Herrera, A. J., de Pablos, R. M., Cano, J., Machado, A. & Venero, J. L., (2004). Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. *Neurobiol Dis.* Vol. 16, No. 1, (Jun, 2004), pp. (190-201).
- Turner, R. & Vink, R., (2007). Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke. *Drug News Perspect.* Vol. 20, No. 4, (May, 2007), pp. (221-6).
- Turner, R. J., Blumbergs, P. C., Sims, N. R., Helps, S. C., Rodgers, K. M. & Vink, R., (2006). Increased substance P immunoreactivity and edema formation following reversible ischemic stroke. *Acta Neurochir Suppl.* Vol. 96, No., 2006), pp. (263-6).
- van der Stelt, M. & Di Marzo, V., (2003). The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. *Eur J Pharmacol.* Vol. 480, No. 1-3, (Nov 7, 2003), pp. (133-50).
- Vink, R., Young, A., Bennett, C. J., Hu, X., Connor, C. O., Cernak, I. & Nimmo, A. J., (2003). Neuropeptide release influences brain edema formation after diffuse traumatic brain injury. *Acta Neurochir Suppl.* Vol. 86, No., 2003), pp. (257-60).
- Vizuete, M. L., Merino, M., Venero, J. L., Santiago, M., Cano, J. & Machado, A., (2000). Histamine infusion induces a selective dopaminergic neuronal death along with an inflammatory reaction in rat substantia nigra. *J Neurochem.* Vol. 75, No. 2, (Aug, 2000), pp. (540-52).
- Wade, T. V. & Schneider, J. S., (2001). Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs. *J Neurosci.* Vol. 21, No. 13, (Jul 1, 2001), pp. (4901-7).
- Wardas, J., Peitraszek, M., Wolfarth, S. & Ossowska, K., (2003). The role of metabotropic glutamate receptors in regulation of striatal proenkephalin expression: Implications for the therapy of Parkinson's disease. *Neurosci.* Vol. 122, No., 2003), pp. (747-756).
- Woie, K., Koller, M. E., Heyeraas, K. J. & Reed, R. K., (1993). Neurogenic inflammation in rat trachea is accompanied by increased negativity of interstitial fluid pressure. *Circ Res.* Vol. 73, No. 5, (Nov, 1993), pp. (839-45).
- Wojtera, M., Sikorska, B., Sobow, T. & Liberski, P. P., (2005). Microglial cells in neurodegenerative disorders. *Folia Neuropathol.* Vol. 43, No. 4, 2005), pp. (311-21).
- Wu, D. C., Teismann, P., Tieu, K., Vila, M., Jackson-Lewis, V., Ischiropoulos, H. & Przedborski, S., (2003). NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. *Proc Natl Acad Sci U S A.* Vol. 100, No. 10, (May 13, 2003), pp. (6145-50).
- Yelnik, J., (2002). Functional anatomy of the basal ganglia. *Mov Disord.* Vol. 17 Suppl 3, No., 2002), pp. (S15-21).

- Yip, J.&Chahl, L. A., (2000). Localization of tachykinin receptors and fos-like immunoreactivity induced by substance P in guinea pig brain. *Clinical and Experimental Pharmacology and Physiology*. Vol. 27, No., 2000), pp. (943-946).

IntechOpen

IntechOpen



Mechanisms in Parkinson's Disease - Models and Treatments

Edited by Dr. Juliana Dushanova

ISBN 978-953-307-876-2

Hard cover, 582 pages

Publisher InTech

Published online 08, February, 2012

Published in print edition February, 2012

Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the substantia nigra. Current PD medications treat symptoms; none halt or retard dopaminergic neuron degeneration. The main obstacle to developing neuroprotective therapies is a limited understanding of the key molecular mechanisms that provoke neurodegeneration. The discovery of PD genes has led to the hypothesis that misfolding of proteins and dysfunction of the ubiquitin-proteasome pathway are pivotal to PD pathogenesis. Previously implicated culprits in PD neurodegeneration, mitochondrial dysfunction, and oxidative stress may also act in part by causing the accumulation of misfolded proteins, in addition to producing other deleterious events in dopaminergic neurons. Neurotoxin-based models have been important in elucidating the molecular cascade of cell death in dopaminergic neurons. PD models based on the manipulation of PD genes should prove valuable in elucidating important aspects of the disease, such as selective vulnerability of substantia nigra dopaminergic neurons to the degenerative process.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Emma Thornton and Robert Vink (2012). The Role of the Neuropeptide Substance P in the Pathogenesis of Parkinson's Disease, *Mechanisms in Parkinson's Disease - Models and Treatments*, Dr. Juliana Dushanova (Ed.), ISBN: 978-953-307-876-2, InTech, Available from: <http://www.intechopen.com/books/mechanisms-in-parkinson-s-disease-models-and-treatments/the-role-of-the-neuropeptide-substance-p-in-the-pathogenesis-of-parkinson-s-disease>

INTeCH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen